?Product Overview?
Ozagrel (CAS: 82571-53-7), a ?potent thromboxane A2 synthase inhibitor?, is an antithrombotic agent with the molecular formula ?C??H??N?O?? and molecular weight ?228.25? ?13. It selectively inhibits thromboxane A2 synthesis, reducing platelet aggregation and vasoconstriction, making it effective in treating ?cerebral thrombosis? and ?acute ischemic stroke? ?13. Available as a white crystalline powder, it is widely used in clinical and research settings for thrombosis-related disorders ?14.

? ?Key Advantages?
? ?High Purity?: ≥99% (HPLC/GC verified), meeting pharmaceutical-grade standards ?12.
? ?Selective Action?: IC?? of ?4 nM? against thromboxane A2 synthase, ensuring targeted efficacy ?3.
? ?Stability?: Stable under ?2–8°C? storage or dry, sealed conditions ?12.

?? ?Application Fields?

• ?Clinical Medicine?: Treatment of ?cerebral thrombosis? and ischemic cerebrovascular diseases ?13.

• ?Research?: Study of platelet aggregation mechanisms and thromboxane-related pathologies ?35.

• ?Pharmaceutical Synthesis?: Intermediate for antithrombotic drug development ?12.

?? ?Quality Certifications?

• Produced under ?GMP-compliant protocols?, adhering to ?USP/EP standards? for export and research ?25.

• Rigorous testing via ?HPLC, NMR, and mass spectrometry? ?56.

• Complies with ?MSDS guidelines? for safe handling and transport ?12.

?? ?Market Insights?
The global antithrombotic drug market is projected to grow at ?CAGR 6.8%? by 2030, driven by increasing cardiovascular disease prevalence ?36. Ozagrel’s role in managing acute thrombotic events positions it as a critical therapeutic agent ?13.